Uterine müllerian adenosarcoma with sarcomatous overgrowth and lung metastasis in a 25-year-old woman

Uterine müllerian adenosarcoma with sarcomatous overgrowth (MASO), uncommon in premenopausal women, is a rare variant of uterine adenosarcomas characterized by a sarcomatous portion constituting >25% of the tumor. Uterine MASO often appears as a benign, protruding cervical polyp. However, in contrast to typical müllerian adenosarcomas (MAs), MASO is a highly aggressive tumor, frequently associated with a fatal outcome. Though very rare in premenopausal women, because of the high aggressiveness and malignant potential, uterine MASO should be considered, even in women of a young age with benign-appearing polypoid masses, and treated aggressively at the time of initial diagnosis without delay. We present herein a case of uterine MASO in a 25-year-old woman with lung metastasis who was lost to follow-up for one month after the initial diagnosis had been established.

Uterus; Adenosarcoma; Sarcomatous overgrowth

[1] Clement P.B.: “Mullerian adenosarcomas of the uterus with sarcomatous overgrowth. A clinicopathological analysis of 10 cases.” Am. J. Surg. Pathol., 1989, 13, 28.

[2] Krivak T.C., Seidman J.D., McBroom J.W., MacKoul P.J., Aye L. M., Rose G.S.: “Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival”. Gynecol. Oncol., 2001, 83, 89.

[3] Gallardo A., Prat J.: “Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challengingthe existence of adenofibroma”. Am. J. Surg. Pathol., 2009, 33, 278.

[4] Hallak M., Peipert J.F., Heller P.B., Sedlacek T.V., Schauer G.M.: “Mullerian adenosarcoma of the uterus with sarcomatous overgrowth”. J. Surg. Oncol., 1992, 51, 68.

[5] Arici D.S., Aker H., Yildiz E., Tasyurt A.: “Mullerian adenosarcoma of the uterus associated with tamoxifen therapy”. Arch. Gynecol. Obstet., 2000, 264, 105.

[6] Clement P.B., Scully R.E.: “Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature”. Hum. Pathol., 1990, 21, 363.

[7] Seidman J.D., Wasserman C.S., Aye L. M., MacKoul P. J., O’Leary T. J.: “Cluster of uterine mullerian adenosarcoma in the Washington, DC metropolitan area with high incidence of sarcomatous overgrowth”. Am. J. Surg. Pathol., 1999, 23, 809.

[8] Nagai Y., Kishimoto T., Kato K., Ozaki D., Kondo F., Kobayashi A. et al.: “Uterine adenosarcoma with sarcomatous overgrowth: a case report with cytology of overgrown poorly differentiated sarcoma and immunohistochemical identification of epithelial microinvasion”. Int. J. Gynecol. Cancer, 2002, 12, 501.

[9] Toyoshima M., Akahira J., Matsunaga G., Niikura H., Ito K., Yaegashi N. et al.: “Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus”. Gynecol. Oncol., 2004, 94, 774.

[10] Farhat M.H., Hobeika E.M., Moumneh G., Nassar A.H.: “Uterine mullerian adenosarcoma with sarcomatous overgrowth fatal recurrence within two weeks of diagnosis: a case report”. J. Med. Case Reports., 2007, 1, 103.